Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2023 09:15 ET | Source: Ceapro Inc.

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and...
November 07, 2023 08:05 ET | Source: Ceapro Inc.

Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology

PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in AustriaYeast beta glucan (YBG) to be the first bio active to be processed at this...
August 29, 2023 09:05 ET | Source: Ceapro Inc.

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace...
August 25, 2023 09:05 ET | Source: Ceapro Inc.

Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the...
July 18, 2023 09:05 ET | Source: Ceapro Inc.

Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro...
July 05, 2023 08:45 ET | Source: Ceapro Inc.

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
June 07, 2023 09:05 ET | Source: Ceapro Inc.

Ceapro Announces Results of 2023 Shareholders’ Meeting

EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
May 25, 2023 09:00 ET | Source: Ceapro Inc.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE...
May 23, 2023 08:45 ET | Source: Ceapro Inc.

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference – – Data...
May 03, 2023 08:05 ET | Source: Ceapro Inc.

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound...